Extensive-stage Small-cell Lung Cancer Clinical Trial
Official title:
Real-world Study of Prophylactic Cranial Irradiation After Immunotherapy Combined With Chemotherapy for Extensive-stage Small Cell Lung Cancer
The prognosis of extensive-stage small cell lung cancer is still very poor, even for those who received chemotherapy and immunotherapy. This experimental study is a real-world research design to evaluate the effectiveness and safety of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer who with first-line chemotherapy combined with immunotherapy.
This study is a prospective trial. This study included ES-SCLC patients who response after standard first-line treatment, and aimed to explore the safety and effectiveness of prophylactic cranial irradiation in this treatment modality. The primary endpoint is progression-free survival in the brain.The secondary endpoints includes OS, PFS. The indicators for evaluating safety are the incidence and severity of adverse events.The exploratory endpoint is the molecular biomarkers for efficacy and toxicity predicting from tumor tissue and peripheral blood TMB. The trial was designed by the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College. The hypothesis is that preventive brain irradiation is safe and effective in the treatment of extensive SCLC combined with chemotherapy and immunotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04985851 -
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
|
N/A | |
| Completed |
NCT01987232 -
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06427369 -
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06223711 -
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
|
Phase 2 | |
| Completed |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04790253 -
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
N/A | |
| Withdrawn |
NCT05572476 -
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05874401 -
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
|
Phase 4 | |
| Not yet recruiting |
NCT06008353 -
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
|
||
| Completed |
NCT04902885 -
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan
|
Phase 3 | |
| Active, not recruiting |
NCT05280470 -
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 2 | |
| Recruiting |
NCT05765825 -
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
|
Phase 2 | |
| Recruiting |
NCT05761977 -
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
|
||
| Active, not recruiting |
NCT05092412 -
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06306560 -
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
|
Phase 2 | |
| Recruiting |
NCT06211036 -
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
|
Phase 3 | |
| Recruiting |
NCT04894591 -
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
|
||
| Not yet recruiting |
NCT06449209 -
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
|
Phase 2 | |
| Not yet recruiting |
NCT06437509 -
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT04878016 -
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
|
Phase 3 |